The U.S. Food and Drug Administration (FDA) has just given a green light for new medicine for chronic weight management. Here are the main factors in this development:

1. Drug Name and Class

The approved medicine is Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist.

2. Intended Use

Wegovy is the permission of the patients suffering from obesity who need to lose weight and people who are overweight with at least one comorbidity.

3. Administration

It is given as a once-weekly subcutaneous injection.

4. Efficacy

Medical tests showed that the people that were taking the medicines of the brand name Wegovy lost an average of 12.4% of their starting weight when compared to those on placebo.

5. Safety Profile

The usual side effects of these drugs are the following- nausea, diarrhea, vomiting, and constipation. They, on the other hand, warn the user of possibly critical side effects, so the drug may be restricted.

6. Lifestyle Modifications

The medicine is to be used along with a strict low-calorie and a high-activity exercise plan.

7. Significance

This approval means a new way of fighting against the obesity, a condition that is encountered by not a few Americans and is known for various health issues.

As is usual with any treatment, consult your doctor for advice before making the final decision to use it or not.